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Abstract 
Purpose: We investigated pharmacological properties, functional alterations and gene 
expressions of the muscarinic receptor system in young and old Goto-Kakizaki (GK) rat 
bladders.   
Materials and methods: Twelve- and 70-week-old male GK rats and age-matched 
male Wistar rats were used in this study.  The bladder functions were estimated by 
voiding behavior studies, cystometric studies, and functional studies using KCl, 
carbachol, and various concentrations of subtype selective muscarinic antagonists, i.e., 
atropine, pirenzepine, methoctramine, and 4-diphenylacetoxy-N-methylpiperidine 
methiodide (4-DAMP). The participation levels of M2 and M3
Results:  In the voiding behavior studies, although there were no significant 
differences in urine output, an age-related decrease in micturition frequency and an 
age-related increase in single voided volume were observed in both GK and Wistar rats. 
In the cystometric studies, although there were no significant differences in maximum 
detrusor pressure or bladder capacity, residual urine volume was significantly increased 
in the 70-week-old GK rats.  In the functional studies, carbachol-induced contractility 
of the detrusor was significantly increased in GK rats of both age groups.  The 
estimated pA
 receptor mRNAs in the 
bladder were investigated by real-time PCR.   
2 values for atropine, pirenzepine, methoctramine, and 4-DAMP indicate 
that the carbachol-induced contractile response is mediated through the M3 receptor 
subtype in all groups.  Furthermore, muscarinic M2 and M3 receptor mRNAs were 
 3 
significantly up regulated in the 70-week-old GK rat bladder.   
Conclusion: Our data indicate that non-insulin-dependent diabetes induces alterations 
in the muscarinic receptor system, which may contribute to the development of diabetic 
cystopathy. 
 4 
 
Diabetic cystopathy, a form of urinary bladder dysfunction, is a major complication of 
diabetes, occurring in 25 to 83% of patients with diabetes mellitus.1, 2  Kaplan et al. 
reported that classical diabetic cystopathy is not the most common urodynamic finding 
in patients with diabetes mellitus and voiding dysfunction, and in fact these patients 
present with variable Pathophysiological findings.3 The streptozotocin (STZ)-induced 
diabetic rat is the most commonly used and well-investigated experimental model for 
type 1 diabetes.4, 5 Alterations of urinary bladder function are also seen in the 
STZ-induced diabetic rats.4, 5  For example, increased urine output, frequent voiding, 
and atonic bladder are observed at least 2 weeks of diabetes induction in this animal 
model.6 However, only limited information is available about type 2 diabetic rat 
cystopathy.  The Goto-Kakizaki (GK) rat represents a spontaneous 
non-insulin-dependent diabetes model.  GK rats are produced from normal Wistar rats 
by repetition of selective breeding, and are a widely accepted genetically determined 
rodent model for human type 2 diabetes.7, 8  This genetic rat model is particularly 
relevant to human type 2 diabetes because defects in glucose-stimulated insulin 
secretion, peripheral insulin resistance, and hyperinsulinemia are seen as early as four 
weeks after birth, and later-occurring abnormalities include insulin secretion and modest 
hyperglycemia.9
  Furthermore, some reports have indicated age-related and diabetes-suffered 
duration-related alterations of bladder functions.
   
10, 11  To get more information on the 
detailed mechanisms of type 2 diabetes-induced alteration of bladder smooth muscles, 
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we investigated bladder contraction using KCl and carbachol with subtype-selective 
muscarinic antagonists as well as muscarinic M2 and M3 receptor mRNAs expression 
levels by real-time polymerase chain reaction (PCR).
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MATERIALS AND METHODS 
Animal model 
  All animal experiments were performed in accordance with the guidelines established 
by the Tottori University Committee for Animal Experimentation.  Six-week-old male 
GK and Wistar rats were purchased from SLC (Shizuoka, Japan).  All rats were kept 
under identical conditions, and had access to food and drinking water ad libitum.  The 
rats were divided randomly into four groups (n = 6-8).  Groups A and B consisted of 
12-week-old Wistar and GK rats, respectively, while Groups C and D consisted of 
70-week-old Wistar and GK rats, respectively.  Upon reaching either 12 or 70 weeks of 
age, the rats were sacrificed with an overdose of pentobarbital (60 mg i.p.).  Blood 
samples were collected from the vena cava, and isolated bladders were used in tissue 
bath experiments or frozen at –80 ℃ for measurement of muscarinic M2 and M3
 
 
receptor mRNAs.   
Serum glucose and serum insulin measurement  
  Serum glucose concentrations in the experimental rats were measured by the 
hexokinase method (Glucose CⅡ, Wako Pure Chemical, Osaka, Japan), which was 
carried out according to the kit manufacturer's instructions in all groups.  In Groups C 
and D, the insulin concentrations were also measured by ELISA according to the 
manufacturer's instructions (Rat Insulin ELISA, Mercodia AB, Uppsala, Sweden). 
 
Voiding behavior studies 
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 Voiding behavior studies were performed according to methods used in our previous 
study12
 
 at 12 or 70 weeks of age in all groups.  All rats received water ad libitum from 
the time they were initially placed in the cage.  The parameters of the micturition 
reflex obtained were micturition frequency, total urine output, and single voided 
volume.   
Cystometr ic studies 
 The cystometric studies were performed according to methods used in our previous 
report12
 
 at 12 or 70 weeks of age in all groups.  The following parameters were 
evaluated according to our previous reports: bladder capacity, maximum detrusor 
pressure during voiding (Pdet), single-voided volume, and residual urine volume. 
Measurement of contractile force in the bladder  
 Functional studies were conducted according to methods used in our previous 
reports.12, 13  Razor blades were used to cut uniform longitudinal strips of the posterior 
wall of the bladder dome (1.5×5 mm).  Changes in the tone of the strips were 
measured isometrically by means of force transducers, and the data were recorded on a 
personal computer (Macintosh G3, Apple Computer, Cupertino, CA, USA) with the use 
of the software program Chart version 3.6.9 and a PowerLab/16sp data acquisition 
system (AD Instruments, Castle Hill, NSW, Australia). Cumulative 
concentration-response curves to carbachol and KCl (100 mmol/l) were constructed.  
Carbachol-induced contractile responses were measured cumulatively in the presence or 
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absence of various concentrations of muscarinic receptor antagonists: pirenzepine 
(PRZ), methoctramine (MTR), 4-diphenylacetoxy-N-methylpiperidine methiodide 
(4-DAMP), and atropine (ATR).13
 
  Antagonists were added 30 minutes prior to the 
administration of carbachol.  After completion of a concentration-response curve, the 
tissue was washed until baseline force returned to the resting level, equilibrated for 30 
minutes, and then the next consecutive concentration-response curve was constructed. 
Real-time PCR (quantification of muscarinic M2 and M3
  To measure muscarinic receptor mRNAs on the detrusor, urothelium was carefully 
peeled under illuminated magnifiers in every rat (Otsuka, Tokyo, Japan).  Muscarinic 
M
 receptor messenger 
RNAs) 
2 and M3 receptor mRNAs in the experimental bladder dome were measured by 
real-time PCR methods according to our previous reports.12, 13  The RNA was purified 
by RNeasy® Fibrous Tissue Mini Kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer's instructions.  A reverse transcriptase (RT) mixture (28 μl) containing 
2 μg of total RNA was made and incubated at 37 ℃ for 60 min according to a 
previously reported method.12,13  Five microliters of the mixture was used for real-time 
PCR, which was carried out with the use of a LightCycler thermal cycler system with a 
LightCycler-FastStart DNA Master Hybridization Probe (Roche Diagnostics, Tokyo, 
Japan) according to the manufacturer's instructions.14  The primers and probe 
sequences specific to the genes of muscarinicM2 (accession number: NM 012527) and 
muscarinic M3 (accession number: NM 031016) receptors were used according to our 
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previous reports.12, 13
 
  The primer and probe of the β-actin (accession number: 
NM_031144) were used from the LightCycler-Primer/Probe Set (rat) (Roche 
Diagnostics).  A total of 15 μl of solution was used for the sample.  PCR products 
were subjected to 2% agarose gel electrophoresis.  The β-actin gene was used as the 
internal standard and analyzed by real-time PCR by using the same RT mixture.    
Data analysis 
  The EC50 and Emax values were obtained by a Macintosh computer (G3) located with 
Chart version 3.6.9 software and a PowerLab/16sp data acquisition system.  The dose 
ratio was obtained from the ratio of EC50 values (the concentration of agonist that 
produces half-maximal contractile responses) for carbachol in the presence or absence 
of an antagonist.  The pA2 values were obtained from Schild plots.15  Schild plots 
were constructed by plotting the log of (dose ratio -1) against the log of the molar 
concentration of the antagonist.  The EC50 values were calculated as geometric means, 
whereas Emax values were calculated as arithmetic means.  The expressions of 
muscarinic M2 and M3
 
 receptor mRNAs were quantified according to the expressions 
of β-actin mRNAs in the experimental rat bladder domes.  A statistical comparison of 
differences between groups was performed using analysis of variance and Fisher's 
multiple comparison tests.  P<0.05 was regarded as the level of significance. 
Drugs and chemicals 
  Carbachol, 4-DAMP, pirenzepine, and methoctramine were purchased from Sigma 
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(St. Louis, MO, USA).  Atropine was purchased from Wako Pure Chemical Industries 
(Osaka, Japan).  All other chemicals were available commercially and of reagent 
grade. 
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RESULTS  
General features of the exper imental animals  
  The data obtained regarding the general features and serum concentrations of insulin 
and glucose in the experimental animals are shown in Table 1 and Figure 1.  The GK 
diabetic rats showed significantly small weight gain by the age of 10 weeks, as well as 
significantly small weight gain during the experimental period (Figure 1).  There was 
no significant difference in the bladder weight between Groups A and B, or Groups C 
and D.  However, the bladder / body weight ratio in Group D was markedly greater 
than that in Groups B and C.
 
  Significantly higher serum glucose levels were 
confirmed at the age of 12 weeks in the GK diabetic rats.  Significantly higher serum 
glucose and lower serum insulin levels than those of the control rats were confirmed in 
the 70-week-old GK diabetic rats.   
Voiding behavior studies  
  Results of voiding behavior studies for the experimental animals are shown in Table 2.  
These studies revealed no significant differences in urine production, micturition 
frequency, or single voided volume between the GK and control rats at either age.  
Although urine production was similar in all groups, age-related alterations in 
micturition frequency and single voided volume were observed.  The older rats 
(Groups C and D) showed significant decreases in micturition frequency and significant 
increases in single voided volume. 
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Cystometr ic studies  
  The results of the cystometric studies are also shown in Table 3.  In these studies, 
although single voided volume in Groups C and D tended to be larger, there were no 
significant differences in Pdet and single voided volume between any of the groups.  
However, the residual urine volume in Group D was markedly greater than those in 
Groups B and C.   
 
Measurement of contractile responses to carbachol and 100 mM KCl 
  The Emax values for the contractile responses of the longitudinal muscles to carbachol 
and KCl (100 mM) were determined (Table 4).  Diabetes-induced detrusor 
hyperreactivity and age-related hyporeactivity by carbachol was observed in these 
experimental rats when normalized by 100 mmol KCl.  However, there were no 
significant differences in the EC50 values with respect to carbachol between any of the 
groups. The pA2 values and slopes of the Schild plots for these muscarinic receptor 
antagonists in the rat detrusor are shown in Table 5.  The pA2 
  These data suggest that in control bladder smooth muscle, contractile responses 
induced by carbachol are mediated through the muscarinic M
values calculated for 
series of muscarinic antagonists were similar in all groups and were rank-ordered as 
ATR > 4-DAMP > MTR > PRZ.  The slopes of the Schild plots for these muscarinic 
receptor antagonists were similar between groups. 
3 receptor subtype, and 
that carbachol does not alter contractile systems according to age or the presence of 
diabetes. 
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Measurement of muscar inic M2 and M3
  Table 6 shows the expressions of muscarinic M
 receptor mRNAs in the rat bladder dome 
2 and M3 receptor mRNAs in the 
bladder dome.  Although the expression levels of muscarinic M2 and M3 receptor 
mRNAs were similar in the younger groups, those of the older GK rats were 
significantly higher than those of age-matched controls.  Furthermore, the control 
group (Group A) had higher expression levels of the muscarinic M3 than the muscarinic 
M2 receptor mRNAs; in all groups, the expression level of the muscarinic M3 receptor 
mRNAs was approximately 2-3 times higher than that of the muscarinic M2 receptor 
mRNAs. 
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DISCUSSION 
  Latifpour and associates demonstrated that significant up-regulation of the 
expressions of muscarinic receptors and hyper-contractility induced by a muscarinic 
receptor agonist, carbachol, in diabetic rat bladder dome.4, 5  Interestingly, those reports 
did not demonstrate significant alterations of EC50 values for carbachol and of Ki values 
of [3H]QNB for muscarinic receptor subtype-selective antagonists. Those findings 
indicated that diabetes-induced alterations of the muscarinic receptor system in the 
bladder are quantitative rather than qualitative.  Tong and associates reported that 
STZ-induced diabetes increases mRNA and protein expressions of M2 and M3 
muscarinic receptors in the urothelium as well as in the muscle layer.16, 17  In our recent 
studies, analyses of diabetes-induced alterations in the bladder using pharmacological, 
biochemical, and biological methods supported their findings.12, 13  Recently, 
Daneshgari and associates reported that diabetic bladders may undergo a transition from 
a compensated to a decompensated state and that this transition in the STZ rat model 
may begin 9 to 12 weeks after induction.11  Thus, the STZ rat model of type 1 diabetes 
has been well investigated and characterized.  However, only limited information is 
available for bladder dysfunction in type 2 diabetic models.  Using 32-week-old 
female GK rats, Miyamae et al. reported that damage to the autonomic nervous system 
and peripheral nerves in the bladder causes a decrease in acetylcholine release during 
bladder contractions, which may be related to voiding dysfunctions in diabetes 
mellitus.18 Yono et al. reported age-related alterations in the biochemical and functional 
properties of the bladder in type 2 diabetic GK rats.  In their reports, the maximum 
 15 
contractile responses to carbachol and ATP, and the release of acetylcholine induced by 
field stimulation, were similar in bladders from GK and control rats until 8 weeks of 
age; however, at the ages of 16 and 32 weeks, GK rats had increased contractile 
responses to carbachol and levels of ATP, along with decreased release of acetylcholine, 
compared to controls.
  
19 
Previously, we reported that diabetes induces an increase in maximum detrusor 
pressure during voiding; this increase occurred by urethral dysfunction associated with 
diabetic neuropathy. 12  In this study, we demonstrated similar tendency of Pdet in GK 
rats; Pdet in 70-week-old GK rats (Group D) tended to be higher than that in 
age-matched Wistar rats (Group C).  However, there was no significant difference 
between Groups C and D.  It may be due to great variation of the data presented.  In 
the present study, we also demonstrated the hypercontractility of detrusor smooth 
muscle to carbachol in GK rats at both ages compared to age-matched control rats.  
These data are similar to those for STZ-induced diabetic rats previously reported.12, 13  
We also demonstrated that 70-week-old GK diabetic rats had significantly increased 
residual urine volume compared to both age-matched control rats and 12-week-old GK 
rats.  These data are particularly interesting, because early-stage STZ-induced diabetic 
rats and late-stage GK rats showed similar patterns of cystopathy.  To clarify the 
mechanisms underlying type 2 diabetic cystopathy, we undertook pharmacological and 
biological examinations.  To confirm these putative changes in the muscarinic receptor 
system, we calculated the pA2 values and their slopes using four subtype nonselective 
and selective muscarinic alterations.  There were no significant differences in the pA2 
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values and slopes between diabetic and non-diabetic rats for any of the muscarinic 
receptor antagonists used in the present study.  The results of the pA2 calculations for 
this series of muscarinic antagonists were similar in all groups, and the rank order of the 
values was: ATR > 4-DAMP > MTR > PRZ.  These findings indicate that alteration of 
the contractile response via the muscarinic M3 receptor subtype is not due to changes in 
muscarinic receptor affinity in diabetic rat detrusor. Rather, such changes appear to be 
the result of quantitative rather than qualitative changes in the muscarinic receptor 
system.  Mutoh and associates previously reported that the rank order of pA2 values 
for these muscarinic antagonists was ATR > 4-DAMP > PRZ > MTR in the rabbit 
bladder dome,20  and we also previously reported that the rank order of pA2 values for 
these muscarinic antagonists in the rat bladder smooth muscle was ATR > 4-DAMP > 
MTR > PRZ.13  Regarding the role of muscarinic receptors, these data suggest that the 
rat detrusor undergoes contractions via the muscarinic M3
  To elucidate the mechanisms underlying diabetes-induced hypercontractility to 
carbachol of the rat detrusor, we measured the expression levels of muscarinic M
 receptor subtype in both 
younger and older GK rats.   
2 and 
M3 receptor mRNAs using real-time PCR.  The results showed that the mRNA levels 
of both muscarinic M2 and M3 receptors were increased under diabetic conditions at 70 
weeks, as compared to age-matched controls.  Based on our previous and present data, 
it appears likely that the overexpressions of muscarinic M2 and M3 receptor mRNAs are 
related to the hypercontractility of detrusor in 70-week-old diabetic rats.12, 13  The 
possible mechanisms of this up-regulation of muscarinic receptors are explained due to 
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decrease in cholinergic nerve density,18 or due to defective neurotransmitter release 
mechanism.21 Miyamae et al. reported decrease in cholinergic nerve density in GK rats, 
18 while Tong et al. reported defective neurotransmitter release mechanism in 
two-week-old STZ induced diabetic rats. 21 The diabetes-associated neuropathy may 
inhibit the release of acetylcholine from cholinergic nerves, in turn inducing the 
overexpression of muscarinic receptors in the diabetic detrusor.18, 19
  In conclusion, our data indicate that non-insulin-dependent diabetes induces 
alterations of the muscarinic receptor system that may contribute to the development of 
diabetic cystopathy. 
  Such 
overexpression may enhance signaling downstream of these receptors and may increase 
detrusor contraction, according to the results of the present organ bath study.   
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Figure legends 
 
Figure 1. Body weight in GK and Wistar rats. 
Data are shown as mean ± SEM of six to eight separated determinations in each group. 
*)significantly different from the same age of Wistar rats.  
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